Stay updated on TAS-102 vs Placebo in Metastatic Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the TAS-102 vs Placebo in Metastatic Gastric Cancer Clinical Trial page.

Latest updates to the TAS-102 vs Placebo in Metastatic Gastric Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedCore content updated with an operating-status notice and a version upgrade from v3.0.2 to v3.2.0.SummaryDifference2%

- Check27 days agoChange DetectedUpdate: version revision changed from v3.0.2 to v3.1.0.SummaryDifference0.0%

- Check34 days agoChange DetectedCore content on drug safety and related topics has been removed, reducing important information about drug safety, counterfeit drugs, pharmaceutical preparations, and substandard drugs.SummaryDifference0.2%

- Check41 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing v3.0.1. The 'Back to Top' navigation element has been removed.SummaryDifference0.1%

- Check48 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.1%

- Check55 days agoChange DetectedThe webpage has undergone significant updates, including the addition of new facility names and locations across various countries, as well as detailed information on drug safety and counterfeit drugs. Notably, the drug trifluridine/tipiracil is highlighted, indicating a focus on its clinical relevance.SummaryDifference7%

Stay in the know with updates to TAS-102 vs Placebo in Metastatic Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TAS-102 vs Placebo in Metastatic Gastric Cancer Clinical Trial page.